FibroGen licenses anemia compounds to Astellas
Following up on an agreement signed in mid-2004, Astellas and FibroGen (fibrotic disease therapeutics) have entered into another agreement for the development and marketing of oral anemia treatments.
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.